Lawver Teri L 4

What Happened
Teri L. Lawver, Senior Vice President & Chief Commercial Officer of Celldex Therapeutics (CLDX), was granted 90,000 derivative securities on June 25, 2026. The Form 4 reports the acquisition as an award/grant of 90,000 shares at $0.00 (derivative), indicating an option/award rather than a cash purchase or sale. The filing shows $0 cash consideration for the grant.

Key Details

• Transaction date: 2026-06-25; Form filed: 2026-06-29 (filed within the typical 2 business-day window).
• Transaction type: Award/Grant (derivative security) — 90,000 shares reported as acquired at $0.00.
• Plan: Award issued under the Issuer’s 2021 Omnibus Equity Incentive Plan (footnote).
• Vesting: 25% vests on June 25, 2027; remaining 75% vests quarterly in equal amounts over the next 12 quarters (footnote).
• Shares owned after transaction: Not disclosed in the provided filing.
• Filing timeliness: No late filing indicated based on the reported dates.

Context
This was a stock option/award grant as part of executive compensation (a derivative award), not an open-market buy or sale. Such grants are typically part of long-term incentive pay and vest over time, so they do not represent an immediate purchase or sale of shares.